Sort
48,018 grants matching “immunotherapy”
Pre-clinical Bruker Albira Si PET/SPECT/CT imaging system
$1,084,326Jason Thanh Lee · Stanford University · S10 · FY2023 · OD
A "Trojan Horse" bispecific antibody strategy for broad filovirus therapeutics
$1,084,177Kartik Chandran · Albert Einstein College Of Medicine · R01 · FY2021 · AI
TARGETING PCD FOR CANCER THERAPY
$1,084,031University Of Michigan At Ann Arbor · P01 · FY2002 · CA
Center for Quantitative Biology: a focus on âomicsâ, from organisms to single cells Supplement 4
$1,082,397Michael L Whitfield · Dartmouth College · P20 · FY2024 · GM
Immune modulation of radiation therapy with Flt3 ligand
$1,081,749Tibor Keler · Celldex Therapeutics, Inc. · R44 · FY2015 · CA
Passive Immunotherapy for Pediatric Mutans Streptococcal Infections
$1,081,587Martin A Taubman · Ada Forsyth Institute, Inc. · R56 · FY2007 · DE
Intravesical Immunotherapy of Spontaneous Canine Invasive Urothelial Carcinoma
$1,081,084David Zaharoff · North Carolina State University Raleigh · U01 · FY2025 · CA
Molecular And Immunopathology Of Experimental And Clinical Ocular Diseases
$1,081,049Chi-Chao Chan · National Eye Institute · ZIA · FY2009 · EY
Immune Escape in Human Cancer: Mechanisms and Therapeutic Implications
$1,081,004Theresa L. Whiteside · University Of Pittsburgh At Pittsburgh · P01 · FY2007 · CA
Regulation And Function Of Retroelements
$1,080,876Henry L. Levin · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2018 · HD
Adoptive T cell Therapy for Pediatric Leukemia
$1,080,868Terry Fry · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Evaluation of Pre-Analytical Factors of Urine Samples for Urine Cancer Cell Cultures (UCCC) --A Non-Invasive Biomarker â in Monitoring Response and Recurrence of Bladder Cancer
$1,080,844Xuefeng Liu · Ohio State University · U01 · FY2025 · CA
Using microfluidics to realize patient-specific anti-cancer immunotherapies
$1,080,800Polly Morrell Fordyce · Stanford University · DP1 · FY2023 · CA
Using microfluidics to realize patient-specific anti-cancer immunotherapies
$1,080,800Polly Morrell Fordyce · Stanford University · DP1 · FY2024 · CA
Using microfluidics to realize patient-specific anti-cancer immunotherapies
$1,080,800Polly Morrell Fordyce · Stanford University · DP1 · FY2025 · CA
CELL THERAPY CORE
$1,080,576Michael I Nishimura · Loyola University Chicago · P01 · FY2015 · CA
POLYVALENT VACCINE--PHASE III TRIAL IN STAGE IV MELANOMA
$1,080,112John Wayne Cancer Institute · R01 · FY2001 · CA
City of Hope Lymphoma SPORE
$1,079,832Stephen J Forma · Beckman Research Institute/City Of Hope · P50 · FY2009 · CA
Point-of-care antimicrobial susceptibility testing based on simultaneous tracking of multi-phenotypic features of single bacterial cells
$1,079,736Shaopeng Wang · Arizona State University-Tempe Campus · R01 · FY2022 · AI
Point-of-care antimicrobial susceptibility testing based on simultaneous tracking of multi-phenotypic features of single bacterial cells
$1,079,736Shaopeng Wang · Arizona State University-Tempe Campus · R01 · FY2021 · AI
Membrane-based vaccine with checkpoint blockade for triple negative breast cancer
$1,079,344Kamal V. Kannan · Metaclipse Therapeutics Corporation · R44 · FY2018 · CA
Bioinformatics, Machine Learning, Systems Biology of Cancers
$1,079,318Javed Khan · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
Developing Novel Therapies for High Risk Pediatric Cancers
$1,079,318Javed Khan · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
Targeting the DNA Damage Response sensor Replication Protein A for first inclass cancer therapy
$1,078,680Katherine Pawelczak · Nerx Biosciences, Inc. · R44 · FY2024 · CA
Broad Spectrum Neutralizing Human Abs to SARS and Related Coronaviruses
$1,078,057Wayne A. Marasco · Dana-Farber Cancer Inst · R01 · FY2014 · AI